Tirzepatide vs Semaglutide | What each one actually is

Short answer: tirzepatide produces greater weight loss, and we now have a head-to-head trial proving it. In the SURMOUNT-5 phase 3b study — published in The New England Journal of Medicine in 2025 — tirzepatide beat semaglutide directly over 72 weeks.

Older comparisons had to hedge, because they were looking at separate trials with different populations and doses. That is no longer necessary. This page covers what each drug is, what the trials found, and how they differ in practice.

What each one actually is

Semaglutide is a GLP-1 receptor agonist. It mimics glucagon-like peptide-1, a gut hormone released after eating, which slows gastric emptying and signals fullness to the brain.

Tirzepatide is a dual agonist — it targets GIP and GLP-1 receptors. GIP is glucose-dependent insulinotropic polypeptide. Tirzepatide mimics two hormones where semaglutide mimics one.

That single difference — one receptor versus two — is the entire mechanistic argument, and it is what the trial results bear out.

What the head-to-head trial found

SURMOUNT-5 (Aronne et al., NEJM, 2025) compared the two directly in adults with obesity but without diabetes, over 72 weeks.

Both differences were statistically significant. Tirzepatide lost roughly 50% more weight than semaglutide, and — worth noting — it was also better tolerated, with half the rate of gastrointestinal side effects severe enough to stop treatment.

One finding that gets overlooked: weight loss was about 6% lower in men than in women across both groups. This trial enrolled more men (35%) than most obesity trials, which the authors believe explains why the absolute numbers came in slightly below earlier studies.

Where the earlier numbers came from

The separate trials that predate the head-to-head are still worth knowing, because they are what most people have read:

Those figures pointed the same direction, but comparing across trials is weaker evidence than comparing within one. SURMOUNT-5 removed that problem — and the gap held.

This is also why the older version of this article said it was "too early to draw definitive conclusions." In 2023 that was a fair caveat. In 2025 it is out of date.

What this means in practice

Tirzepatide is the more effective option on the current evidence. If the goal is maximum weight reduction and both are available, the trial supports tirzepatide.

Semaglutide is not a weak drug. A 13.7% reduction is substantial — comfortably better than anything available a decade ago. It is also more widely studied, available in an oral form, and often cheaper.

Tolerability favours tirzepatide on this data, which matters because GI side effects are the main reason people stop GLP-1 treatment.

The choice is not permanent. Both require titration from a low starting dose, and both are stopped or switched under clinical supervision rather than abruptly.

Dosing and titration

Neither drug works at its full dose immediately. Both are escalated gradually over roughly 16 weeks to let the gut adapt — which is why GI side effects cluster during dose escalation rather than at maintenance.

This is also why "which is stronger" is a slightly misleading question at the start: for the first month or two, you are on a sub-therapeutic dose of whichever you choose.

Storage

Both are refrigerated at 2–8 °C before first use, and neither should be frozen.

If you are more used to oil-based injectables — which must never be refrigerated — this is the reverse rule, and mixing them up degrades the product either way. How to store tirzepatide covers the specifics.

For research-grade peptide supplied as lyophilised powder, the powder itself is stable at room temperature; it is the reconstituted solution that needs cold storage. Reconstituting semaglutide covers the arithmetic.

What to check before buying either

Both drugs are heavily counterfeited. The WHO issued a medical product alert on falsified semaglutides in June 2024, and the FDA has warned about counterfeit Ozempic inside the legitimate US supply chain.

·         Batch-linked certificate of analysis from an independent laboratory, with a report number and a lot number matching your product

·         Total content in mg, and how many doses that represents once reconstituted

·         Cold-chain shipping — both compounds need temperature control in transit

·         A testing history, not a single old result

Buying semaglutide safely covers the sourcing side in more detail.

FAQ

Is tirzepatide better than semaglutide?

Yes, on the current evidence. In the SURMOUNT-5 head-to-head trial, tirzepatide produced 20.2% weight loss against semaglutide's 13.7% over 72 weeks, with fewer gastrointestinal side effects severe enough to stop treatment.

What is the difference between them?

Semaglutide targets one receptor (GLP-1). Tirzepatide targets two (GLP-1 and GIP). That additional receptor is why tirzepatide produces greater weight loss.

How much weight do you lose on each?

In the head-to-head trial: an average of 22.8 kg on tirzepatide and 15.0 kg on semaglutide at 72 weeks.

Which has fewer side effects?

Tirzepatide, in the head-to-head data — 2.7% discontinued for GI adverse events against 5.6% on semaglutide. Both produce nausea, vomiting and constipation, mostly during dose escalation.

Can you take semaglutide and tirzepatide together?

No. They act on overlapping pathways, and there is no evidence for combining them — only for switching under supervision.

Which is cheaper?

Semaglutide is generally less expensive, and it has more approved versions in circulation including an oral form. Cost is a real consideration, and the effectiveness gap is not so large that price becomes irrelevant.

Do both need to be refrigerated?

Yes. Store both at 2–8 °C before first use and never freeze them.

Where to buy GLP-1 peptides

PandaRoids stocks GLP-1 peptides and a wider range of weight-management research compounds, including Sema-Pep and Tirze-Pep — the rebranded names for Dragon Pharma's semaglutide and tirzepatide respectively.

Whichever you choose, check the batch documentation, confirm the total content in mg, and ask how it ships. Both compounds need cold-chain handling and both are documented counterfeiting targets, so documentation is the only meaningful measure of what you are getting.

This article is educational and is not medical advice. Semaglutide and tirzepatide are prescription medicines in most jurisdictions.